Supplement | Sample reports

GUIDELINE UPDATES - This guideline was last updated 01/07/2022

Sample cervical screening reports

CERVICAL SCREENING	LOW RISK FOR SIGNIFICANT CERVICAL ABNORMALITY
SPECIMEN	Cervical – ThinPrep
TEST RESULTS	PCR for Oncogenic HPV and genotype: HPV 16 – Not detected HPV 18 – Not detected HPV (not 16/18) – Not detected
RECOMMENDATION	Rescreen in five years.

CERVICAL SCREENING	UNSATISFACTORY
SPECIMEN	Cervical – SurePath
TEST RESULTS	PCR for Oncogenic HPV and genotype: Unsatisfactory
RECOMMENDATION	Retest within six weeks.

CERVICAL SCREENING	UNSATISFACTORY
SPECIMEN	Cervical – ThinPrep
TEST RESULTS	PCR for Oncogenic HPV and genotype: HPV 16 – Not detected HPV 18 – Not detected HPV (not 16/18) – Detected Liquid Based Cytology (LBC), Image assisted: Unsatisfactory
RECOMMENDATION	Repeat screening test in six weeks.

CERVICAL SCREENING	INTERMEDIATE RISK FOR SIGNIFICANT CERVICAL ABNORMALITY
SPECIMEN	Cervical – SurePath
TEST RESULTS	PCR for Oncogenic HPV and genotype: HPV 16 – Not detected HPV 18 – Not detected HPV (not 16/18) – Detected Liquid Based Cytology (LBC), Manually Read: There is no evidence of a squamous intraepithelial lesion or malignancy Endocervical component: Present
RECOMMENDATION	Repeat test in 12 months.

CERVICAL SCREENING	INTERMEDIATE RISK FOR SIGNIFICANT CERVICAL ABNORMALITY
SPECIMEN	Cervical – SurePath
TEST RESULTS	PCR for Oncogenic HPV and genotype: HPV 16 – Not detected HPV 18 – Not detected HPV (not 16/18) – Detected Liquid Based Cytology (LBC), Image Assisted: Low grade intra-epithelial lesion (LSIL) Endocervical component: Present
RECOMMENDATION	Repeat test in 12 months.

CERVICAL SCREENING	HIGHER RISK FOR SIGNIFICANT CERVICAL ABNORMALITY
SPECIMEN	Cervical – ThinPrep
TEST RESULTS	PCR for Oncogenic HPV and genotype: HPV 16 – Not detected HPV 18 – Detected HPV (not 16/18) – Not detected Liquid Based Cytology (LBC), Manually Read: High grade squamous intra-epithelial lesion (HSIL) Endocervical component: Present
RECOMMENDATION	Referral for Colposcopic assessment.

CERVICAL SCREENING	HIGHER RISK FOR SIGNIFICANT CERVICAL ABNORMALITY
SPECIMEN	Cervical – SurePath
TEST RESULTS	PCR for Oncogenic HPV and genotype: HPV 16 – Detected HPV 18 – Not detected HPV (not 16/18) – Not detected Liquid Based Cytology (LBC), Manually Read: Unsatisfactory
RECOMMENDATION	Referral for Colposcopic assessment.

CERVICAL SCREENING	HIGHER RISK FOR SIGNIFICANT CERVICAL ABNORMALITY
SPECIMEN	Cervical – ThinPrep
TEST RESULTS	PCR for Oncogenic HPV and genotype: HPV 16 – Not detected HPV 18 – Not detected HPV (not 16/18) – Detected Liquid Based Cytology (LBC), Image Assisted: Possible high grade squamous intra-epithelial lesion (pHSIL) Endocervical component: Not identified
RECOMMENDATION	Referral for Colposcopic assessment.

CERVICAL SCREENING	HIGHER RISK FOR SIGNIFICANT CERVICAL ABNORMALITY
SPECIMEN	Cervical – SurePath
TEST RESULTS	PCR for Oncogenic HPV and genotype: HPV 16 – Detected HPV 18 – Not detected HPV (not 16/18) – Detected Liquid Based Cytology (LBC), Manually Read: High grade squamous intra-epithelial lesion (HSIL) Endocervical component: Not identified
RECOMMENDATION	Referral for Colposcopic assessment.

CERVICAL SCREENING	HIGHER RISK OF SIGNIFICANT CERVICAL ABNORMALITY
SPECIMEN	Cervical – ThinPrep
TEST RESULTS	PCR for Oncogenic HPV and genotype: HPV 16 – Detected HPV 18 – Not detected HPV (not 16/18) – Not detected Liquid Based Cytology (LBC), Image Assisted: There is no evidence of a squamous intraepithelial lesion or malignancy Endocervical component: Present
RECOMMENDATION	Referral for Colposcopic assessment.

CERVICAL SCREENING	HIGHER RISK OF SIGNIFICANT CERVICAL ABNORMALITY
SPECIMEN	Cervical – SurePath
TEST RESULTS	PCR for Oncogenic HPV and genotype: HPV 16 – Not detected HPV 18 – Not detected HPV (not 16/18) – Detected Liquid Based Cytology (LBC), Manually Read: There is no evidence of a squamous intraepithelial lesion or malignancy Endocervical component: Present
RECOMMENDATION	In view of the previously reported abnormality referral for colposcopic assessment.

CERVICAL SCREENING	HIGHER RISK OF SIGNIFICANT CERVICAL ABNORMALITY
SPECIMEN	Cervical – ThinPrep
TEST RESULTS	PCR for Oncogenic HPV and genotype: HPV 16 – Not detected HPV 18 – Not detected HPV (not 16/18) – Detected Liquid Based Cytology (LBC), Image Assisted: Low grade squamous intra-epithelial lesion (LSIL) Endocervical component: Present
RECOMMENDATION	In view of the previously reported abnormality referral for colposcopic assessment.

CERVICAL SCREENING	HIGHER RISK OF SIGNIFICANT CERVICAL ABNORMALITY
SPECIMEN	Cervical – SurePath
TEST RESULTS	PCR for Oncogenic HPV and genotype: HPV 16 – Not detected HPV 18 – Not detected HPV (not 16/18) – Detected Liquid Based Cytology (LBC), Manually Read: Atypical endocervical cells of undetermined significance There is no evidence of a squamous intraepithelial lesion or malignancy
RECOMMENDATION	Referral for colposcopic assessment by a gynaecologist with expertise in the evaluation of suspected malignancies or by a gynaecological oncologist.

CERVICAL SCREENING	HIGHER RISK OF SIGNIFICANT CERVICAL ABNORMALITY
SPECIMEN	Cervical – ThinPrep
TEST RESULTS	PCR for Oncogenic HPV and genotype: HPV 16 – Not detected HPV 18 – Detected HPV (not 16/18) – Not detected Liquid Based Cytology (LBC), Image Assisted: Possible high grade glandular lesion The findings suggest possible adenocarcinoma-in-situ
RECOMMENDATION	Referral for colposcopic assessment by a gynaecologist with expertise in the evaluation of suspected malignancies or by a gynaecological oncologist.

CERVICAL SCREENING	HIGHER RISK OF SIGNIFICANT CERVICAL ABNORMALITY
SPECIMEN	Cervical – ThinPrep
TEST RESULTS	PCR for High Risk HPV and genotype: HPV 16 – Detected HPV 18 – Not detected HPV (not 16/18) – Not detected Liquid Based Cytology (LBC) Image Assisted: Squamous cell carcinoma There are abnormal cells that indicate origin from an invasive squamous cell carcinoma Endocervical component: Present
RECOMMENDATION	Colposcopy is recommended. Patient should be referred to a gynaecological oncologist or a gynaecological cancer centre for assessment.

CERVICAL SCREENING	HIGHER RISK OF SIGNIFICANT CERVICAL ABNORMALITY
SPECIMEN	Cervical – SurePath
TEST RESULTS	PCR for High Risk HPV and genotype: HPV 16 – Not detected HPV 18 – Detected HPV (not 16/18) – Not detected Liquid Based Cytology (LBC), Manually Read: Endocervical adenocarcinoma
RECOMMENDATION	Colposcopy is recommended. Patient should be referred to a gynaecological oncologist or a gynaecological cancer centre for assessment.

Sample stand alone LBC reports

SPECIMEN

Cervical – SurePath

TEST RESULTS

Liquid Based Cytology (LBC) Manually Read:

Low grade squamous intra-epithelial lesion (LSIL)
Endocervical component: Present

RECOMMENDATION

This woman is under specialist management, therefore no management recommendation is made.

SPECIMEN

Cervical – ThinPrep

TEST RESULTS

Liquid Based Cytology (LBC) Image assisted:

High grade squamous intra-epithelial lesion (HSIL)
Endocervical component: Present

RECOMMENDATION

This woman is under specialist management, therefore no management recommendation is made.

Reports for self-collected samples

CERVICAL SCREENING	LOW RISK OF SIGNIFICANT CERVICAL ABNORMALITY
SPECIMEN	Lower vaginal sample – Self collected
TEST RESULTS	PCR for Oncogenic HPV and genotype: HPV 16 – Not detected HPV 18 – Not detected HPV (not 16/18) – Not detected
RECOMMENDATION	Rescreen in five years.

CERVICAL SCREENING
SPECIMEN	Lower vaginal sample – Self collected
TEST RESULTS	PCR for Oncogenic HPV and genotype: HPV 16 – Not detected HPV 18 – Not detected HPV (not 16/18) – Detected
RECOMMENDATION	Collect a cervical sample for LBC within six weeks.

CERVICAL SCREENING	HIGHER RISK OF SIGNIFICANT CERVICAL ABNORMALITY
SPECIMEN	Lower vaginal sample – Self collected
TEST RESULTS	PCR for Oncogenic HPV and genotype: HPV 16 – Detected HPV 18 – Not detected HPV (not 16/18) – Not detected
RECOMMENDATION	Refer for colposcopic assessment. Cervical sample for LBC can be obtained at time of that assessment.

CERVICAL SCREENING	UNSATISFACTORY
SPECIMEN	Lower vaginal sample – Self collected
TEST RESULTS	PCR for Oncogenic HPV and genotype: Unsatisfactory
RECOMMENDATION	Retest within six weeks.

Author(s):

A/Professor Lyndal Anderson — Co-author
Professor Marion Saville — Co-author
Professor Gordon Wright — Co-author
Cancer Council Australia Cervical Cancer Screening Guidelines Working Party — Co-author

WEBSITE UPDATES - This website was last updated 01/07/2022

Clinical Guidelines

Supplement: Sample reports

Supplement: Sample reports

Sample cervical screening reports

Sample stand alone LBC reports

Reports for self-collected samples